Article Text

Download PDFPDF
Review: antibiotics active against atypical pathogens do not improve community acquired pneumonia more than β lactam antibiotics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with community acquired pneumonia (CAP), how do antibiotics active against atypical pathogens (AAAAPs) compare with β lactam antibiotics for effectiveness?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★★☆ Infectious disease ★★★★★★☆


Embedded ImageData sources:

Cochrane Central Controlled Trials Register, Medline, and EMBASE/Excerpta Medica (to December 2003); conference proceedings; registration authorities; reference lists of review articles and retrieved studies; and pharmaceutical companies conducting trials on AAAAPs.

Embedded ImageStudy selection and assessment:

randomised, blinded (investigators, patients, and outcome assessors), controlled trials (RCTs) that compared AAAAPs (fluoroquinolones, macrolides, and ketolides) with β lactam antibiotics (penicillins and cephalosporins) in patients with radiographically confirmed CAP.

Embedded ImageOutcomes:

failure to achieve clinical cure or improvement and all cause …

View Full Text


  • For correspondence: Dr G D Mills, Waikato Hospital, Hamilton, New Zealand.

  • Source of funding: Waikato District Health Board.